CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers
Release Date: 02/13/2026
A Discussion with Dr. Alison Christy: 2026 Ted Burns Humanism in Neurology Award Winner
Neurology Minute
Dr. Stacey Clardy talks with Dr. Alison Christy, the recipient of the 2026 Ted Burns Humanism in Neurology Award, about her inspiring career, innovative approaches to neurology education, and how she fosters compassion and creativity in medicine.
info_outline
Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021
Neurology Minute
Dr. Tesha Monteith talks with Ayesha Sohail about her abstract titled "Global Burden of Headache Disorders in Older Adults (Aged ≥ 55 Years) from 1990-2021: An Analysis of Epidemiology, Trends, and Socioeconomic Disparities." Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 3
Neurology Minute
In the final episode of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the study results and their implications for improving clinical practice. Read more about this abstract on the .
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss how this technology was developed and how it has evolved. Read more about this abstract on the .
info_outline
2026 AAN President's Award Recipient - Dr. Walter J. Koroshetz
Neurology Minute
Dr. Greg Cooper talks with Dr. Walter J. Koroshetz about his advice for early neurologists. Read more about the .
info_outline
A Path to Preventing Cognitive Impairment Due to Alzheimer's Disease
Neurology Minute
Dr. Greg Cooper and Dr. Eric Reiman discuss emerging antibody therapies for preclinical Alzheimer's disease and the clinical, regulatory, and equity considerations shaping prevention trials and future care. Show citation: Reiman EM, Alexander RC, Langbaum JB, et al. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. Lancet Neurol. 2026;25(3):268-278. doi:
info_outline
Diagnostic Utility and Prognostic Significance of Circulating Tumor Cell Assay CNSide in Patients With Suspicion for Leptomeningeal Metastases - Part 1
Neurology Minute
In the first part of this series, Dr. Justin Abbatemarco and Dr. Shreya Louis discuss the background and evolving terminology around circulating tumor DNA, cell‑free DNA and CSF‑based testing in neurology. Read more about this abstract on the .
info_outline
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the clinical trial design, including the objectives and methods. Read more about this abstract on the .
info_outline
April 6, 2026 Capitol Hill Report: Proposed Budget Cuts, New Bills
Neurology Minute
In this episode, Dr. Andy Southerland reviews the Capitol Hill Report from April 6th, focusing on news related to appropriations and several new bills. Stay updated with what’s happening on the hill by visiting . Learn how you can get involved with .
info_outline
History of Letters to the Editor
Neurology Minute
As we celebrate the 75th anniversary of Neurology®, Drs. Jeff Ratliff, Steven Galetta, and Robert Griggs discuss the history and evolution of the Letters to the Editor section. Join the conversation by visiting the .
info_outlineDr. Greg Cooper and Dr. David G. Coughlin discuss the role of αSyn-SAAs in diagnosing DBL and their relationship with Alzheimer's disease biomarkers.
Show citation:
Show transcript:
Dr. Greg Cooper:
Hi, this is Dr. Greg Cooper. I just finished interviewing Dr. David Coughlin for this week's Neurology Podcast. For today's Neurology Minute, I'm hoping you can tell us the main points of your paper.
Dr. David Coughlin:
The main points of this paper in my mind is that α-Synuclein seed amplification assays from cerebrospinal fluid samples is useful in confirming the presence of synuclein pathology in people with clinically suspected dementia with Lewy bodies. But also that, for people who have synuclein positivity, that the presence of Alzheimer's disease mixed pathology is associated with a worse cognitive progression over time.
Dr. Greg Cooper:
Thank you Dr. Coughlin, for that summary and for all of your work on this topic. Please check out this week's podcast to hear the full interview and read the full article published in Neurology, CSF α-Synuclein Seed Amplification Assays and Alzheimer's Disease Biomarkers in Dementia with Lewy Bodies. Thank you.